New drug duo aims to boost fight against tough head and neck cancers
NCT ID NCT05366166
Summary
This study is testing whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can better control a difficult-to-treat form of head and neck cancer. It will involve about 45 adults with locally advanced cancer who have not had prior treatment. The main goal is to see if this combination helps keep the cancer from growing or spreading for at least one year after treatment starts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Medical University of South Carolina (MUSC)
Charleston, South Carolina, 29425, United States
-
UNC Lineberger
Chapel Hill, North Carolina, 27514, United States
-
University of Louisville, Brown Cancer Center
Louisville, Kentucky, 40202, United States
Conditions
Explore the condition pages connected to this study.